Bayer hits the brakes on hemophilia drug trial; Big Pharma goes nuts for nanotech;

@FierceBiotech: Industry Voices: Who will figure out how to make a business out of fecal transplants? Feature | Follow @FierceBiotech

@JohnCFierce: Bristol-Myers' "smart bomb" deal pushes Ambrx 12-month deal tally to $715M. More | Follow @JohnCFierce

@RyanMFierce: Sanofi lets go of rights to Regeneron's antibodies in ophthalmology in $65M agreement. Article | Follow @RyanMFierce

> Bayer has hit the brakes on development of a Phase II/III trial of BAY 86-6150 in some hemophilia patients over concerns about safety. Article

> Reuters' Ben Hirschler covers a spate of nanotech drug alliances with Big Pharma companies--including Pfizer ($PFE), Amgen ($AMGN), Sanofi ($SNY) and AstraZeneca ($AZN). And MIT inventor Bob Langer finds himself on the winning end of the deals. Article

> An FDA panel of outside experts unanimously voted against Delcath Systems' ($DCTH) drug-device combination product for treating cancer. Story

> The Wellcome Trust has pledged up to £5 million to fund GlaxoSmithKline's ($GSK) open research of new treatments for diseases in the developing world. Release

> Park Vale Capital will tap advice from members of the Academy of Medical Sciences to inform the company's late-stage biotech bets. Item

Medical Device News

@FierceMedDev: Implant successfully predicts human epilepsy seizures. Item | Follow @FierceMedDev

@MarkHFierce: A Dx to predict prostate cancer recurrence produced some hopeful early results. DxExtra | Follow @MarkHFierce

 @DamianFierce: Life Tech posts tepid quarterly results as Thermo waits with $13.6B. News | Follow @DamianFierce

> Medtronic lops off 230 spinal jobs, endures FDA blemish. Story

> Zimmer grabs PA startup for cutting-edge knee treatment. Article

> FDA panel rips Delcath drug/device cancer treatment. News

Pharma News

@FiercePharma: Regeneron, Eylea now 7 for 7 in beating Wall Street forecasts. More | Follow @FiercePharma

@EricPFierce: Medicare spending growth so slow that Independent Payment Board won't be in play for 2015 drug pricing pharma. Item | Follow @EricPFierce

> J&J issue in South Korea reminiscent of OTC problems here. More

> Slow Medicare spending protects pharma from payment board intravention. News

> Gilead profits surge 63%, but not where Wall Street expected. Article

> Arena pulls app for weight-loss drug Belviq in EU. Story

And Finally… GlaxoSmithKline "listened" to online chatter about vaccines for two months with data-mining tech. Article

Suggested Articles

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.

The phase 2/3 clinical trial linked REGN-COV2 to a 57% decline in medical visits associated with COVID-19 in the 29 days after treatment.

Drug companies often face steep challenges when entering new markets for the first time. LianBio is here to help.